Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05241834 · ClinicalTrials.gov registry record · Phase 1
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
A Phase 1 study of Carcinoma, Non-Small Cell Lung and Thyroid Neoplasms, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 16
- Study locations
NCT05241834: Active Phase 1 study of Carcinoma, Non-Small Cell Lung and Thyroid Neoplasms, sponsored by Eli Lilly and Company.
NCT05241834 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Thyroid Neoplasms that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 70 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (78% lower). The trial reports 16 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05241834, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Thyroid Neoplasms, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 16
- Study locations
Study Summary
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene). Participation could last up to 24 months (2 years) and possibly longer if the disease does not get worse.
Primary Outcome
DLT rate
Conditions Studied
Interventions
- DRUG LOXO-260
Study Locations (16)
California
- UCLA Medical Center - Los Angeles
- UCSF Medical Center at Mission Bay - San Francisco
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Ohio
- Cleveland Clinic Foundation - Cleveland
- Ohio State University Hospital - Columbus
Other
- Centre Leon Berard - Lyon
- Institut Gustave Roussy (Igr) - Villejuif
Georgia
- Emory University - Atlanta
Illinois
- University of Chicago Medicine-Comprehensive Cancer Center - Chicago
Michigan
- University of Michigan - Ann Arbor
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2022-03-23 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
What the registry record for NCT05241834 still lists
NCT05241834 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (78% lower).
The record links to 2 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which LOXO-260 is the first listed.
NCT05241834 lists 16 locations in 12 states (California, Massachusetts, Ohio).
Frequently Asked Questions
What is clinical trial NCT05241834 about?
NCT05241834 is a clinical study titled "A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment". The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene). Participation could last up to 24 months (2 years) and possibly longer if the disease do...
What is the current status of trial NCT05241834?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2022-03-23. Estimated completion is 2026-06.
What conditions does trial NCT05241834 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Thyroid Neoplasms.
What interventions are being tested in trial NCT05241834?
The interventions under investigation include: LOXO-260 (DRUG).
Who is sponsoring clinical trial NCT05241834?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05241834 being conducted?
This trial has 16 study locations across California, Georgia, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05241834's enrollment target sits among peer trials
70 83rd of 130 higher than 46 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
RECRUITING · Phase 1
-
A Study of LY4175408 in Participants With Advanced Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI